Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations.

Details

Ressource 1Download: BIB_8873EB254E5F.P001.pdf (282.37 [Ko])
State: Public
Version: author
Serval ID
serval:BIB_8873EB254E5F
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations.
Journal
Swiss Medical Weekly
Author(s)
Taverna C., Bargetzi M., Betticher D., Gmür J., Gregor M., Heim D., Hess U., Ketterer N., Lerch E., Matthes T., Mey U., Pabst T., Renner C.
ISSN
1424-3997 (Electronic)
ISSN-L
0036-7672
Publication state
Published
Issued date
2010
Volume
140
Pages
w13054
Language
english
Notes
Publication types: Comparative Study ; Consensus Development Conference ; Journal Article ; Research Support, Non-U.S. Gov't ; Review Publication Status: epublish
Abstract
The treatment of multiple myeloma has undergone significant changes in the recent past. The arrival of novel agents, especially thalidomide, bortezomib and lenalidomide, has expanded treatment options and patient outcomes are improving significantly. This article summarises the discussions of an expert meeting which was held to debate current treatment practices for multiple myeloma in Switzerland concerning the role of the novel agents and to provide recommendations for their use in different treatment stages based on currently available clinical data. Novel agent combinations for the treatment of newly diagnosed, as well as relapsed multiple myeloma are examined. In addition, the role of novel agents in patients with cytogenetic abnormalities and renal impairment, as well as the management of the most frequent side effects of the novel agents are discussed. The aim of this article is to assist in treatment decisions in daily clinical practice to achieve the best possible outcome for patients with multiple myeloma.
Keywords
Aged, Antineoplastic Agents/adverse effects, Antineoplastic Agents/therapeutic use, Biopsy, Needle, Bone Marrow/drug effects, Bone Marrow/pathology, Bone Marrow Transplantation, Boronic Acids/adverse effects, Boronic Acids/therapeutic use, Combined Modality Therapy, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Resistance, Neoplasm, Evidence-Based Medicine, Humans, Middle Aged, Multiple Myeloma/diagnosis, Multiple Myeloma/drug therapy, Neoplasm Recurrence, Local/drug therapy, Neoplasm Recurrence, Local/pathology, Plasma Cells/drug effects, Plasma Cells/pathology, Pyrazines/adverse effects, Pyrazines/therapeutic use, Retreatment, Type="Geographic">Switzerland, Thalidomide/adverse effects, Thalidomide/analogs & derivatives
Pubmed
Web of science
Create date
25/08/2010 12:46
Last modification date
20/08/2019 14:47
Usage data